NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

2 months ago

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical…

Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry

2 months ago

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell…

Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry

2 months ago

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell…

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

2 months ago

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical…

Stemtech Corporation – Stemtech Healthsciences India Pvt Ltd Announces Strategy for Market Entry

2 months ago

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell…

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

2 months ago

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of…

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

2 months ago

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of…

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

2 months ago

Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large…

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

2 months ago

Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large…

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

2 months ago

Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large…

Show more Posts
Show previous Posts